UBS Group’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-487
| Closed | -$8.87K | – | 9174 |
|
|
2024
Q2 | $8.87K | Sell |
487
-501
| -51% | -$9.12K | ﹤0.01% | 6616 |
|
|
2024
Q1 | $18.2K | Buy |
988
+442
| +81% | +$8.14K | ﹤0.01% | 5793 |
|
|
2023
Q4 | $10.7K | Buy |
+546
| New | +$10.7K | ﹤0.01% | 6221 |
|
|
2023
Q3 | – | Sell |
-3,263
| Closed | -$67.2K | – | 8893 |
|
|
2023
Q2 | $67.2K | Buy |
3,263
+2,453
| +303% | +$50.5K | ﹤0.01% | 5240 |
|
|
2023
Q1 | $16.6K | Sell |
810
-2,034
| -72% | -$41.6K | ﹤0.01% | 6138 |
|
|
2022
Q4 | $63.7K | Buy |
2,844
+1,205
| +74% | +$27K | ﹤0.01% | 5393 |
|
|
2022
Q3 | $34K | Buy |
1,639
+1,153
| +237% | +$23.9K | ﹤0.01% | 5664 |
|
|
2022
Q2 | $11K | Sell |
486
-1,658
| -77% | -$37.5K | ﹤0.01% | 6843 |
|
|
2022
Q1 | $59K | Buy |
2,144
+1,901
| +782% | +$52.3K | ﹤0.01% | 5322 |
|
|
2021
Q4 | $9K | Sell |
243
-1,706
| -88% | -$63.2K | ﹤0.01% | 7834 |
|
|
2021
Q3 | $80K | Buy |
1,949
+1,437
| +281% | +$59K | ﹤0.01% | 4909 |
|
|
2021
Q2 | $20K | Sell |
512
-914
| -64% | -$35.7K | ﹤0.01% | 6263 |
|
|
2021
Q1 | $51K | Buy |
1,426
+150
| +12% | +$5.37K | ﹤0.01% | 5528 |
|
|
2020
Q4 | $40K | Buy |
1,276
+958
| +301% | +$30K | ﹤0.01% | 5394 |
|
|
2020
Q3 | $9K | Buy |
+318
| New | +$9K | ﹤0.01% | 6091 |
|